Metabolism

6 Items

per page
Set Descending Direction
  1. anti-FTO (human), mAb (AG103)
    AG-20A-0092
    AG-20A-0092-C05050 µg
    CHF 300.00
    AG-20A-0092-C100100 µg
    CHF 390.00
    Immunohistochemical staining of FTO with anti-FTO (human), mAb (AG103) (Prod. No. AG-20A-0092) in brain, hypothalamus and paraventricular nucleus (5~10 μg/ml). This antibody has been tested in immunohistochemistry, analyzed by an anatomic patholo
  2. anti-FTO, mAb (FT86-4)
    AG-20A-0064
    AG-20A-0064-C05050 µg
    CHF 270.00
    AG-20A-0064-C100100 µg
    CHF 350.00
    Immunoprecipitation of recombinant human FTO using anti-FTO (human), mAb (FT86-4) (Prod. No. AG-20A-0064). Recombinant human FTO proteins at different concentrations were precipitated by FT86-4. The precipitated proteins were separated by SDS-PAGE, electr
  3. anti-Hairy and Enhancer of Split 1 (HES1), mAb (7H11)
    AG-20T-0400
    AG-20T-0400-C100100 µg
    CHF 380.00
    Western blot analysis using anti-HES1, mAb (7H11) (Prod. No. AG-20T-0400) in cell lysates. Lane1: HeLa cell lysate; Lane 2: HT29 cell lysate; Lane 3: BeWo cell lysate.
  4. anti-MPC-2, mAb (JCM-1)
    AG-20B-0071
    AG-20B-0071-C100100 µg
    CHF 540.00
  5. anti-Nampt (Visfatin/PBEF), mAb (OMNI379)
    AG-20A-0034
    AG-20A-0034-C05050 µg
    CHF 290.00
    AG-20A-0034-C100100 µg
    CHF 410.00
    Immunoprecipitation of recombinant human Nampt(Visfatin/PBEF) proteins using anti-Nampt (Visfatin-PBEF), mAb (OMNI379) (Prod. No. AG-20A-0034). Recombinant human Nampt(Visfatin/PBEF) proteins at different concentrations were precipitated. The precipitated
  6. anti-PARP-10 [ARTD10] (human), mAb (5H11)
    AG-20T-0004
    AG-20T-0004-L0011 ml
    CHF 380.00
    Immunofluorescence using anti-PARP-10 [ARTD10] (human), mAb (5H11). Method: T47D mammary carcinoma cells were stained by indirect immunofluorescence and analysed. Prior to fixation and staining, the cells were treated with or without 50nm leptomyci

6 Items

per page
Set Descending Direction
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.